The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

(2017) Christopher Abbosh et al.   NATURE

Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA

(2017) Shicheng Guo et al.   NATURE GENETICS

Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer

(2016) M. Jamal-Hanjani et al.   ANNALS OF ONCOLOGY

Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients

(2016) Song Xu et al.   CANCER LETTERS

Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer

(2016) Tatsuo Ohira et al.   CANCER SCIENCE

Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment

(2016) Junji Uchida et al.   CANCER SCIENCE

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

(2016) J. C. Thompson et al.   CLINICAL CANCER RESEARCH

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

(2016) C. Karlovich et al.   CLINICAL CANCER RESEARCH

Circulating Biomarkers in Non–Small-Cell Lung Cancer: Current Status and Future Challenges

(2016) Alexios Matikas et al.   Clinical Lung Cancer

Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC

(2016) Yi-chen Zhang et al.   EXPERT OPINION ON PHARMACOTHERAPY

Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

(2016) Qing Zhou et al.   Journal of Hematology & Oncology

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

(2016) Shuhang Wang et al.   Journal of Hematology & Oncology

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer

(2016) Shuhang Wang et al.   Journal of Hematology & Oncology

A Novel EGFR C797 Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture–Based Next-Generation Sequencing Assay

(2016) Roopika Menon et al.   Journal of Thoracic Oncology

O.02: Plasma Next Generation Sequencing of Over 5,000 Advanced Non-Small Cell Lung Cancer Patients With Clinical Correlations

(2016) Philip C. Mack et al.   Journal of Thoracic Oncology

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

(2016) Karen L. Reckamp et al.   Journal of Thoracic Oncology

Liquid cancer biopsy: the future of cancer detection?

(2016) The Lancet Oncology   LANCET ONCOLOGY

Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer

(2016) Fumio Imamura et al.   LUNG CANCER

Clinical and biological significance of circulating tumor cells in cancer

(2016) Takaaki Masuda et al.   Molecular Oncology

Cancer therapy: an evolved approach

(2016) Cassandra Willyard   NATURE

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

(2016) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer

(2016) B. Levy et al.   ONCOLOGIST

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

(2016) Jacob J. Chabon et al.   Nature Communications

Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer

(2016) Victoria Villaflor et al.   Oncotarget

Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing

(2016) Ke-Zhong Chen et al.   Scientific Reports

Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study

(2016) Nicolas Pécuchet et al.   PLOS MEDICINE

Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence

(2016) E-E Ke et al.   Therapeutic Advances in Respiratory Disease

Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors

(2016) Shuhang Wang et al.   Frontiers of Medicine

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

(2015) T. Mok et al.   CLINICAL CANCER RESEARCH

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients

(2015) C. P. Paweletz et al.   CLINICAL CANCER RESEARCH

Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA

(2015) J. Uchida et al.   CLINICAL CHEMISTRY

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

(2015) Wei Sun et al.   Journal of Hematology & Oncology

Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls

(2015) Shu Xia et al.   LUNG CANCER

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

(2015) David M. Hyman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges

(2015) Rajyalakshmi Luthra et al.   Cancers

Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002

(2014) S. Couraud et al.   CLINICAL CANCER RESEARCH

Circulating Tumor DNA as a Liquid Biopsy for Cancer

(2014) E. Heitzer et al.   CLINICAL CHEMISTRY

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study

(2014) Mariam Jamal-Hanjani et al.   PLOS BIOLOGY

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Existing and Emerging Technologies for Tumor Genomic Profiling

(2013) Laura E. MacConaill   JOURNAL OF CLINICAL ONCOLOGY

The Cancer Genome Atlas Pan-Cancer analysis project

(2013) John N Weinstein et al.   NATURE GENETICS

Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions

(2013) J. F. Gainor et al.   ONCOLOGIST

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Opportunities and Challenges Associated with Clinical Diagnostic Genome Sequencing

(2012) Iris Schrijver et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu

(2012) J. De Grève et al.   LUNG CANCER

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

(2012) K. Ohashi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

(2011) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

(2010) K. Suda et al.   CLINICAL CANCER RESEARCH

The Human Genome Project at 10 years: A teachable moment

(2010) James P Evans   GENETICS IN MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE